BOW015 (Infliximab-EPIRUS)

Infliximab-EPIRUS · Epirus Biopharmaceuticals (Switzerland) GmbH

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for BOW015 (Infliximab-EPIRUS), covering 2016-02-17 to 2016-02-17. Get the full timeline:

Most recent: Clinical Trial Update: BOW015 (Infliximab-EPIRUS) and Infliximab in Patients With Active Rheumatoid Arthritis: The UNIFORM Study [Phase 3]

See pricing